As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Gilead Sciences, seeing a 22% boost ... bolstered by the still high demand for their weight-loss and diabetes drugs, which ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

S hould a high dividend yield raise a yellow flag for investors? In some cases, yes. But not always. There are select stocks ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ ... Some recovery was aided by the ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...